Caribou Biosciences, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.34
- 52-Week Range
- $0.31 – $2.49
- Market Cap
- $35.23M
- P/E (TTM)
- —
- EPS (TTM)
- -1.03
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.46
- PEG Ratio
- —
- Return on Equity
- -93.80%
- Return on Assets
- -42.34%
- Gross Margin
- 0.00%
- Operating Margin
- -1140.56%
- Profit Margin
- 0.00%
- Current Ratio
- 4.97
- Debt/Equity
- 0.34
- Total Debt
- $26.34M
- Free Cash Flow
- $-58.63M
- Revenue Growth
- -26.90%
- Earnings Growth
- —
- Enterprise Value
- $-33.23M
Market Snapshot
About
Caribou Biosciences, Inc. is a clinical-stage biotechnology company headquartered in Berkeley, California, developing off-the-shelf CAR-T cell therapies for the treatment of cancer. The company utilizes its proprietary CRISPR genome editing platform to develop next-generation cell therapies with improved anti-tumor activity and reduced manufacturing complexity. Caribou's lead programs target hematologic malignancies and are designed to be manufactured from healthy donor cells rather than a patient's own cells, potentially enabling faster treatment and lower costs. The company was founded by CRISPR pioneer Dr. Jennifer Doudna and has built significant intellectual property around CRISPR-based cellular therapies.